title: [Stroke code impact on the efficacy of thrombolytic treatment].
abstract: OBJECTIVE
  Most stroke patients arrive to emergency rooms too late, many times beyond the therapeutic window for thrombolysis. The activation of a Stroke Code (SC)has proven to be effective in decreasing the latency time for starting therapy in clinical trials. However, its usefulness in routine clinical practice is uncertain. The aim of this study was to determine the feasibility of applying an SC in the daily clinical practice and to evaluate its impact on the efficacy of t-PA thrombolytic treatment.
  
  
  METHODS
  We included middle-cerebral artery stroke patients treated with IV t-PA from June 2000 to December 2001 who were categorized into three periods of 6 months each. The influence of SC activation on the latency time, arterial recanalization and early neurological recovery was evaluated.
  
  
  RESULTS
  Forty-eight patients were prospectively studied. A significant increase in the number of t-PA treated patients was observed in the three periods (4.8%, 5.3% and 8%). A significant progressive decrease (p = 0.036) in the overall delay to start t-PA was observed (from 161.4 to 130 minutes). The proportion of t-PA treated patients in whom SC was activated increased gradually (p = 0.032). SC activation reduced time from symptom onset to hospital arrival (p = 0.013) as well as the "door-to-needle"time (p = 0.049). The rate of early recanalization (p = 0.027) and neurological recovery (p = 0.036) at 48 hours was significantly higher in patients in whom SC was activated than in those in whom SC was not.
  
  
  CONCLUSIONS
  SC activation is very useful in the management of acute stroke, increasing the rate of t-PA treated patients and improving the clinical outcome.
authors.affiliation: Unidad Cerebrovascular, Servicio de Neurología, Hospital Vall d'Hebron, Barcelona, España. alsa@hg-vhebron.es
authors.forename: José
authors.initials: J
authors.lastname: Alvarez-Sabín
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Molina
authors.forename: Sonia
authors.initials: S
authors.lastname: Abilleira
authors.forename: Joan
authors.initials: J
authors.lastname: Montaner
authors.forename: Fernando
authors.initials: F
authors.lastname: García Alfranca
authors.forename: Xavier
authors.initials: X
authors.lastname: Jiménez Fabrega
authors.forename: Juan
authors.initials: J
authors.lastname: Arenillas
authors.forename: Rafael
authors.initials: R
authors.lastname: Huertas
authors.forename: Marc
authors.initials: M
authors.lastname: Ribó
authors.forename: Manuel
authors.initials: M
authors.lastname: Quintana
authors.forename: Agustin
authors.initials: A
authors.lastname: Codina
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004185:Disability Evaluation; D004632:Emergency Medical Services / Q000458:organization & administration*; D005240:Feasibility Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator